{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:15:22Z","timestamp":1767960922392,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.2353\/jmoldx.2006.060089","type":"journal-article","created":{"date-parts":[[2006,12,21]],"date-time":"2006-12-21T13:51:20Z","timestamp":1166709080000},"page":"604-612","source":"Crossref","is-referenced-by-count":33,"title":["Allele-Specific Polymerase Chain Reaction for the Imatinib-Resistant KIT D816V and D816F Mutations in Mastocytosis and Acute Myelogenous Leukemia"],"prefix":"10.1016","volume":"8","author":[{"given":"Christopher L.","family":"Corless","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patina","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Bainbridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Gatter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Clifton","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Granter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2353\/jmoldx.2006.060089_bib1","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.20.6.1692","article-title":"Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT positive malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2006.060089_bib2","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","article-title":"Biology of gastrointestinal stromal tumors","volume":"22","author":"Corless","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2006.060089_bib3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejca.2003.11.025","article-title":"Use of c-KIT\/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"40","author":"Debiec-Rychter","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.2353\/jmoldx.2006.060089_bib4","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2006.060089_bib5","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.2353\/jmoldx.2006.060089_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.gastro.2004.11.020","article-title":"Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants","volume":"128","author":"Debiec-Rychter","year":"2005","journal-title":"Gastroenterology"},{"key":"10.2353\/jmoldx.2006.060089_bib7","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1038\/sj.bjc.6601819","article-title":"Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation","volume":"90","author":"Wakai","year":"2004","journal-title":"Br J Cancer"},{"key":"10.2353\/jmoldx.2006.060089_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(05)70097-8","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations","volume":"6","author":"Wardelmann","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.2353\/jmoldx.2006.060089_bib9","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"key":"10.2353\/jmoldx.2006.060089_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.2353\/jmoldx.2006.060089_bib11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0889-8588(05)70303-8","article-title":"A proposed classification of mastocytosis incorporating molecular genetics","volume":"13","author":"Longley","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.2353\/jmoldx.2006.060089_bib12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0145-2126(01)00046-7","article-title":"Mastocytosis: molecular mechanisms and clinical disease heterogeneity","volume":"25","author":"Metcalfe","year":"2001","journal-title":"Leuk Res"},{"key":"10.2353\/jmoldx.2006.060089_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00062752-200401000-00009","article-title":"Clinical, genetic, and therapeutic insights into systemic mast cell disease","volume":"11","author":"Tefferi","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"10.2353\/jmoldx.2006.060089_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.2353\/jmoldx.2006.060089_bib15","doi-asserted-by":"crossref","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A: KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders. A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood epub June 1, 2006","DOI":"10.1182\/blood-2006-04-015545"},{"key":"10.2353\/jmoldx.2006.060089_bib16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0889-8588(03)00089-3","article-title":"Mast cell proliferative disorders: current view on variants recognized by the World Health Organization","volume":"17","author":"Valent","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.2353\/jmoldx.2006.060089_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"key":"10.2353\/jmoldx.2006.060089_bib18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"Buttner","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.2353\/jmoldx.2006.060089_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","article-title":"Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis","volume":"113","author":"Fritsche-Polanz","year":"2001","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2006.060089_bib20","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.2353\/jmoldx.2006.060089_bib21","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.2353\/jmoldx.2006.060089_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1525-1578(10)60552-1","article-title":"c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation","volume":"7","author":"Yanagihori","year":"2005","journal-title":"J Mol Diagn"},{"key":"10.2353\/jmoldx.2006.060089_bib23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","article-title":"One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes","volume":"162","author":"Sotlar","year":"2003","journal-title":"Am J Pathol"},{"key":"10.2353\/jmoldx.2006.060089_bib24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.2353\/jmoldx.2006.060089_bib25","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.2353\/jmoldx.2006.060089_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2003.10.006","article-title":"Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"key":"10.2353\/jmoldx.2006.060089_bib27","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.2353\/jmoldx.2006.060089_bib28","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060089_bib29","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"10.2353\/jmoldx.2006.060089_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajh.20211","article-title":"Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience","volume":"77","author":"Hennessy","year":"2004","journal-title":"Am J Hematol"},{"key":"10.2353\/jmoldx.2006.060089_bib31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.leukres.2003.09.001","article-title":"Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis","volume":"28","author":"Musto","year":"2004","journal-title":"Leuk Res"},{"key":"10.2353\/jmoldx.2006.060089_bib32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.2353\/jmoldx.2006.060089_bib33","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C","article-title":"Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis","volume":"83","author":"Worobec","year":"1998","journal-title":"Cancer"},{"key":"10.2353\/jmoldx.2006.060089_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.2353\/jmoldx.2006.060089_bib35","first-page":"920","article-title":"KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication","volume":"89","author":"Beghini","year":"2004","journal-title":"Haematologica"},{"key":"10.2353\/jmoldx.2006.060089_bib36","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/sj.leu.2403870","article-title":"Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia","volume":"19","author":"Goemans","year":"2005","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060089_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.leukres.2004.10.005","article-title":"Imatinib mesylate in the treatment of core binding factor leukemias with KIT mutations. A report of three cases","volume":"29","author":"Cairoli","year":"2005","journal-title":"Leuk Res"},{"key":"10.2353\/jmoldx.2006.060089_bib38","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0002-9440(10)61103-0","article-title":"KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size","volume":"160","author":"Corless","year":"2002","journal-title":"Am J Pathol"},{"key":"10.2353\/jmoldx.2006.060089_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1383-5718(02)00077-3","article-title":"Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR","volume":"517","author":"McKinzie","year":"2002","journal-title":"Mutat Res"},{"key":"10.2353\/jmoldx.2006.060089_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"10.2353\/jmoldx.2006.060089_bib41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0002-9440(10)63120-3","article-title":"KIT mutations are common in testicular seminomas","volume":"164","author":"Kemmer","year":"2004","journal-title":"Am J Pathol"},{"key":"10.2353\/jmoldx.2006.060089_bib42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.leu.2403307","article-title":"Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography","volume":"18","author":"Deininger","year":"2004","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060089_bib43","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/carcin\/23.6.943","article-title":"Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression","volume":"23","author":"Parsons","year":"2002","journal-title":"Carcinogenesis"},{"key":"10.2353\/jmoldx.2006.060089_bib44","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1038\/sj.onc.1208832","article-title":"Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens","volume":"24","author":"Dominguez","year":"2005","journal-title":"Oncogene"},{"key":"10.2353\/jmoldx.2006.060089_bib45","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060089_bib46","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060089_bib47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157810603510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157810603510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T05:14:52Z","timestamp":1555996492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157810603510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S1525157810603510"],"URL":"https:\/\/doi.org\/10.2353\/jmoldx.2006.060089","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}